Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to Prolactin
News Feb 11, 2011
Stem Cell Therapeutics Corp. has announced that it has been granted a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,884,072- entitled, "Prolactin induced increase in neural stem cell number." The claims contained within this issued patent cover methods of using an effective amount of prolactin to increase stem cell numbers in mammals suspected of having neurological diseases.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows: "This issued patent and other anticipated patents for the use of prolactin greatly assist the protection and capture of shareholder value for this therapeutic program. The important exclusivity that has been granted for the use of prolactin today combined with ever increasing scientific evidence supporting the use of prolactin builds upon the wealth of intellectual property that SCT possesses. We look forward to the continued advancement of this program in the future."